Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
Sandra Michiels,1– 3 Sandra Tricas-Sauras,2 Adriano Salaroli,3 Dominique Bron,3 Philippe Lewalle,3 Katrijn Vanschoenbeek,4 Hélène A Poirel,4 Fati Kirakoya-Samadoulougou1 1Center for Research in Epidemiology, Biostatistics and Clinical Research, School of Public Health, Université Libre de Bruxelles,...
Saved in:
| Main Authors: | Michiels S, Tricas-Sauras S, Salaroli A, Bron D, Lewalle P, Vanschoenbeek K, Poirel HA, Kirakoya-Samadoulougou F |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-09-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/imatinib-adherence-and-persistence-in-patients-with-chronic-myeloid-le-peer-reviewed-fulltext-article-PPA |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01) -
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01) -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)